Is PT-141 (Bremelanotide) Legal in New York? How to Access It Legally

HealthRX.com

Vyleesi is legal by prescription; compounded PT-141 is not

Print or save as PDF

See the public record for Bremelanotide

  • FDA status / Approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not approved for / HSDD in men or postmenopausal women; enhancing sexual performance [1]
  • Form / 1.75 mg subcutaneous autoinjector, prescription only [1][2]
  • Boxed warning and REMS / None [1][2]
  • Compounded or research-use PT-141 / Not Vyleesi, not FDA-approved [3][1]
  • Dosing per label / Not more than one dose in 24 hours; more than 8 doses a month not recommended [1]

Is bremelanotide FDA-approved?

Yes. FDA approved bremelanotide as Vyleesi on June 21, 2019 (NDA 210557); the application was originally held by AMAG and is now held by Cosette Pharmaceuticals [1][2]. It is a prescription-only 1.75 mg subcutaneous injection given with a prefilled autoinjector, and the label carries no boxed warning and no risk evaluation and mitigation strategy (REMS) [1][2].

Vyleesi is indicated for premenopausal women with acquired, generalized HSDD: low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].

Is PT-141 the same thing as Vyleesi?

No. Vyleesi is the FDA-approved bremelanotide product. Products sold as compounded or research-use peptides under the name PT-141 are not Vyleesi and are not FDA-approved drugs. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1].

Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026), does not appear in any category on FDA's bulk-substance lists, and is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [4][5][6].

Questions worth asking

Choose the questions you want to keep

What the label says to weigh

The label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1]. Each dose transiently raises blood pressure and lowers heart rate. Maximal increases in clinical studies were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].

Nausea was reported by 40.0% of Vyleesi patients versus 1.3% on placebo; 13% needed an anti-nausea medicine and 8% stopped the trials because of it [1]. Pre-treating with 8 mg oral ondansetron 30 minutes before a dose did not reduce nausea in a phase 4 study of 228 healthy women, and the label does not recommend it [1]. Focal hyperpigmentation was reported by 1% of patients given up to 8 doses a month versus none on placebo [1]. Because Vyleesi may significantly decrease exposure to oral naltrexone, the label says to avoid using it with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction, citing the severe consequence of treatment failure [1].

What is the labeled dosing?

The label's regimen is 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with not more than one dose in 24 hours. More than 8 doses a month is not recommended, and the label says to stop if symptoms have not improved after 8 weeks [1].

Is PT-141 legal in New York?
Bremelanotide is FDA-approved and prescription only as Vyleesi [1][2]. This page does not describe New York-specific rules. Compounded or research-use PT-141 is not Vyleesi and is not FDA-approved [3].
Do I need a prescription for bremelanotide?
Yes. Vyleesi is prescription only [1][2].
Can men get a PT-141 prescription?
Vyleesi is not indicated for HSDD in men or to enhance sexual performance [1]. An early PT-141 study reported dose-dependent increases in erectile activity in men, but that is not an approved use [7].
Is compounded PT-141 the same as Vyleesi?
No. Compounded PT-141 is not Vyleesi or an FDA-approved drug, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3]. Bremelanotide does not appear in any category on FDA's bulk-substance lists [4][5].
What are the most common side effects of bremelanotide?
In the pooled phase 3 trials: nausea 40.0% versus 1.3% on placebo, flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4%, and headache 11.3% versus 1.9% [1].
Show all 7 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration.
  3. Official web page.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. Official web page.
  7. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
PT-141 New York: evidence summary chart
Image: HealthRX.com. Full PT-141 New York guide and sources at healthrx.com/peptide-legal-pt-141.